# A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

> **NCT01518712** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
- **DRUG:** B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)

## Key facts

- **NCT ID:** NCT01518712
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518712, "A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01518712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*